ReviewCost effectiveness and resource allocation : C/E2026
A systematic review of the cost-utility of dapagliflozin for managing chronic kidney disease.
Review in Cost effectiveness and resource allocation : C/E, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a significant public health concern. Dapagliflozin has been demonstrated to improve the quality of life for patients with CKD. This systematic review aimed to summarize the available evidence regarding the costs and cost-utility of dapagliflozin in managing CKD.
methodsA systematic literature search was conducted from inception to October 24, 2025, using MEDLINE, EMBASE, and Scopus. Titles and abstracts were screened, followed by an eligibility assessment of full texts. The quality of the studies was evaluated using the Quality of Health Economic Studies (QHES) and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklists. Cost-utility results were synthesized narratively.
resultsThe search strategies identified a total of 305 records, of which 8 articles were ultimately included in the review based on specified inclusion and exclusion criteria. All cost-utility studies were conducted over time horizons ranging from a lifetime to twenty years, with most outcomes derived from a single clinical trial. The highest incremental cost-utility ratio for dapagliflozin ($72,057.91/Quality-Adjusted Life Year) was reported in the USA. According to the available studies, adding dapagliflozin to standard care for CKD management is considered cost-effective from both the healthcare system and payer perspectives.
conclusionsIncorporating dapagliflozin into standard care for managing CKD is generally regarded as cost-effective from both the healthcare system and payer perspectives. While dapagliflozin shows promise economically, further population-based studies are needed to confirm these findings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.